|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1990-7-12
|
|
pubmed:abstractText |
1. The effect of Lambert-Eaton myasthenic syndrome (LEMS) immunoglobulin G (IgG) on Ca2+ channels in undifferentiated mouse neuroblastoma x rat glioma hybrid cells (NG 108 15) was studied using the whole-cell patch clamp technique. 2. Sustained inward Ca2+ channel currents were evoked by depolarizing pulses from holding potentials of -80 and -40 mV, and were blocked by 5 microM-nitrendipine (L-type currents). Transient inward Ca2+ channel currents were activated from a holding potential of -80 mV by small depolarizing steps (T-type currents). Noradrenaline (10 microM) was without effect on transient currents. 3. LEMS IgG selectively reduced sustained (L-type) Ca2+ channel current amplitudes evoked from either holding potential used. In the presence of nitrendipine (5 microM), there was no significant effect of LEMS IgG on the remaining transient (T-type) Ca2+ channel current amplitudes. 4. Studies of the potential for maximal inward current indicated that voltage sensitivities of both L- and T-type Ca2+ channel current amplitudes were unaffected by LEMS IgG, whether recorded in the presence or absence of nitrendipine. LEMS IgG had no significant effect on the time-to-peak or decay of Ca2+ channel currents. 5. It is concluded that LEMS IgG acts selectively to cause functional loss of L-type, but not T-type, Ca2+ channels in NG 108 15 cells. Any effect of LEMS IgG on N-type channels (not present in these undifferentiated cells) was not studied here. LEMS IgG also acts at motor nerve terminal Ca2+ channels leading to muscle weakness. Thus antigenic similarities must exist between L-type channels in NG 108 15 cells and Ca2+ channels at motor nerve terminals.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-13339282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2410796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2414666,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2443646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2447652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2450991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2451016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2451017,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2469160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2838124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2907138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-2992356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-302922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-316102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-3392676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-3479929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-3662451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-4330759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-6111072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-6114283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-6270629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-6584877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2161458-6655585
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-3751
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
421
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
293-308
|
|
pubmed:dateRevised |
2010-9-9
|
|
pubmed:meshHeading |
pubmed-meshheading:2161458-Action Potentials,
pubmed-meshheading:2161458-Animals,
pubmed-meshheading:2161458-Antibodies, Neoplasm,
pubmed-meshheading:2161458-Calcium Channels,
pubmed-meshheading:2161458-Cell Line,
pubmed-meshheading:2161458-Glioma,
pubmed-meshheading:2161458-Humans,
pubmed-meshheading:2161458-Immunoglobulin G,
pubmed-meshheading:2161458-Lambert-Eaton Myasthenic Syndrome,
pubmed-meshheading:2161458-Mice,
pubmed-meshheading:2161458-Neuroblastoma,
pubmed-meshheading:2161458-Nitrendipine,
pubmed-meshheading:2161458-Norepinephrine,
pubmed-meshheading:2161458-Tumor Cells, Cultured
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line.
|
|
pubmed:affiliation |
Department of Pharmacology, Royal Free Hospital Medical School, London.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
